Advertisement

Topics

Clinical Trials About "A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)" RSS

04:42 EDT 22nd May 2018 | BioPortfolio

We list hundreds of Clinical Trials about "A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)" on BioPortfolio

We have published hundreds of A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD) news stories on BioPortfolio along with dozens of A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD) Clinical Trials and PubMed Articles about A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD) Companies in our database. You can also find out about relevant A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD) Drugs and Medications on this site too.

Showing "Study Evaluate ALKS 5461 Subjects With Major Depressive" Clinical Trials 1–25 of 30,000+

Extremely Relevant

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.


A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

This study will evaluate the efficacy of ALKS 5461 when administered daily for 4 weeks to adults with Major Depressive Disorder (MDD) and inadequate response to antidepressant therapy.

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study

This study will evaluate the efficacy and safety of ALKS 5461.


A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers

This study will evaluate the impact of CYP3A4 induction on the single-dose pharmacokinetics of ALKS 5461.

A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users

This study will evaluate the abuse potential of ALKS 5461.

A Water Consumption Study of ALKS 5461 in Healthy Volunteers

This study will evaluate the impact of water consumption on the pharmacokinetics of ALKS 5461.

Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function

This study will evaluate the effect of various degrees of renal function on the pharmacokinetics and safety of ALKS 5461.

A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.

A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors

To better understand the safety and tolerability of ALKS 4230 in humans

Relevant

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 3831 in subjects with schizophrenia.

A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

The primary objective of this study is to evaluate the long term safety and tolerability of ALKS 3831 in subjects with schizophrenia.

Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

The purpose of this trial is to evaluate the efficacy and safety of risperidone versus placebo in subjects with Major Depressive Disorder with sub-optimal response to antidepressant therapy.

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

This study will assess the gastrointestinal (GI) tolerability of ALKS 8700 in adult subjects with RRMS

A Study to Evaluate SAGE-217 in Subjects With Moderate to Severe Major Depressive Disorder

This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in up to 62 subjects diagnosed with moderate to severe Major Depressive Disorder.

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder

Study Of 323U66 SR In Major Depressive Disorder

This study was designed to evaluate the efficacy and safety in major depressive disorder patients.

A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

This study will evaluate the efficacy of ALKS 3831 in adult subjects with acute exacerbation of schizophrenia.

SA4503 8-Week Study in Major Depressive Disorder (MDD)

The purpose of this study is to determine the efficacy of SA4503 compared to placebo in the treatment of subjects with major depressive disorder (MDD). Secondary, to evaluate the safety of SA4503 compared to placebo in subjects with MDD.

Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder

To evaluate the overall safety and tolerability profile of two dose levels of DVS-233 SR during 6 months of open-label treatment in elderly outpatients with major depressive disorder.

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) (the EVOLVE-1 Study)

This study will evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder

The purpose of this research study is to determine the effectiveness of 2 target doses of R228060 in comparison with placebo during 6 weeks of treatment in moderately to severely depressed adult subjects with major depressive disorder. Approximately 488 subjects will be involved in the study.

A Study Of New Medicine (GSK 372475) For The Treatment Of Depression

To evaluate the efficacy, safety and tolerability of GSK372475 compared with placebo in the treatment of outpatients subjects with major depressive disorder to exhibit decreased pleasure, interest and energy.

Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder

The purpose of this study is to evaluate the effectiveness, safety and tolerability of an escitalopram combination treatment compared to single treatments, and to placebo in patients with major depressive disorder.

A Study of CX157 (Tyrima) for the Treatment of Depression

The purpose of this study is to examine the efficacy of CX157 as compared to placebo in subjects with Major Depressive Disorder (MDD). Secondary objectives are to evaluate the safety and tolerability and steady state pharmacokinetic profile of CX157 in these subjects.

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Primary Objective: To compare the efficacy and safety of DVS-233 SR versus placebo treatment in reducing the relapse rate of depressive symptoms in subjects with major depressive disorder (MDD), and to compare the percentages of relapse in terms of time to relapse between DVS-233 SR and placebo treatment groups by using survival analysis. Secondary Objective: To assess the response of subjects on DVS-233 SR versus placebo for the clinical global evaluation, functionality, gene...


More From BioPortfolio on "A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)"

Advertisement
Quick Search
Advertisement
Advertisement